设计具有延迟治疗效应的治疗性癌症疫苗试验
治疗性癌症疫苗通过免疫机制间接作用,可能导致生存曲线延迟分离,违背比例风险假设,使常规log-rank检验设计损失把握度。本文提出两种基于分段加权log-rank检验的样本量与把握度计算方法,将延迟效应纳入设计,理论推导与实证研究显示,与标准做法相比,考虑延迟效应可大幅减少样本量并达到目标把握度。
要点
- 治疗性癌症疫苗可能因免疫机制导致临床效应延迟出现,使生存曲线延迟分离。
- 常规log-rank检验忽略延迟效应会损失把握度,违背比例风险假设。
- 分段加权log-rank检验可将延迟效应纳入设计,大幅减少样本量并达到目标把握度。
核心结论
- 考虑延迟效应的分段加权log-rank检验设计可大幅减少样本量并达到目标把握度,优于标准做法。
研究设计与样本
- 方法学研究,提出两种基于分段加权log-rank检验的样本量与把握度计算方法,并通过理论推导与实证研究验证。
主要发现
- 治疗性癌症疫苗的间接作用机制可能导致临床效应延迟出现,造成生存曲线延迟分离。
- 忽略延迟效应的常规log-rank检验设计会损失把握度。
- 所提出的两种方法将延迟效应纳入设计,与标准做法相比可大幅减少样本量并达到目标把握度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Arming the immune system against cancer has emerged as a powerful tool in oncology during recent years. Instead of poisoning a tumor or destroying it with radiation, therapeutic cancer vaccine, a type of cancer immunotherapy, unleashes the immune system to combat cancer. This indirect mechanism-of-action of vaccines poses the possibility of a delayed onset of clinical effect, which results in a delayed separation of survival curves between the experimental and control groups in therapeutic cancer vaccine trials with time-to-event endpoints. This violates the proportional hazard assumption. As a result, the conventional study design based on the regular log-rank test ignoring the delayed effect would lead to a loss of power. In this paper, we propose two innovative approaches for sample size and power calculation using the piecewise weighted log-rank test to properly and efficiently incorporate the delayed effect into the study design. Both theoretical derivations and empirical studies demonstrate that the proposed methods, accounting for the delayed effect, can reduce sample size dramatically while achieving the target power relative to a standard practice. Copyright © 2016 John Wiley & Sons, Ltd.
引用
- Xu Z, Zhen B, Park Y, et al. Designing therapeutic cancer vaccine trials with delayed treatment effect. Stat Med. 2016. PMID: 27807870. doi:10.1002/sim.7157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。